90721-35-0

Basic information

• Product Name: 5-BROMO-8-ISOQUINOLINEAMINE
• Synonyms: 5-BROMO-8-ISOQUINOLINEAMINE;8-Isoquinolinamine,5-bromo-(9CI);5-Bromo-isoquinolin-8-ylamine;8-Amino-5-bromoisoquinoline;5-bromo-8-aminoisoquinoline;5-Bromoisoquinolin-8-amine;5-Bromoisoquinolin-8-amine, 5-Bromo-2-azanaphthalen-8-amine;5-BroMo-8-isoquinolinaMine
• CAS NO: 90721-35-0
• Molecular Formula: C9H7BrN2
• Molecular Weight: 223.06928
• Product Categories: ISOQUINOLINE
• Mol File: 90721-35-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 186-190 °C
• Boiling Point: 370.3 °C at 760 mmHg
• Flash Point: 177.7 °C
• Appearance: Off-white to brown/Crystalline Powder
• Density: 1.649 g/cm³
• Vapor Pressure: 1.12E-05mmHg at 25°C
• Refractive Index: 1.732
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 5.22±0.36(Predicted)
• CAS DataBase Reference: 5-BROMO-8-ISOQUINOLINEAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-8-ISOQUINOLINEAMINE(90721-35-0)
• EPA Substance Registry System: 5-BROMO-8-ISOQUINOLINEAMINE(90721-35-0)

Safety Data

• Hazard Codes: T
• Statements: 25-36
• Safety Statements: 26-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 90721-35-0(Hazardous Substances Data)

Usage

General Description

5-Bromo-8-isoquinolineamine is a chemical compound that belongs to the class of isoquinoline derivatives. It is used primarily in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceutical drugs and compounds. The compound is known for its potential therapeutic properties, with studies suggesting its role in treating certain diseases and conditions. It is also utilized in research and development activities, particularly in the study of organic reactions and the creation of new drug candidates. Additionally, 5-Bromo-8-isoquinolineamine has demonstrated antimicrobial and antifungal activities, making it a valuable compound in the field of medicinal chemistry and drug discovery. Despite its potential benefits, the compound should be handled and utilized with caution due to its potential hazards and risks.

InChI:InChI=1/C9H7BrN2/c10-8-1-2-9(11)7-5-12-4-3-6(7)8/h1-5H,11H2

Upstream product

• 34784-04-8 5-bromoisoquinoline 
• 63927-23-1 5-bromo-8-nitroisoquinoline 

Downstream Products

• 679433-94-4 5-bromo-8-fluoroisoquinoline 

Relevant articles and documents

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

The SAR of a series of brain penetrant, trisubstituted thiophene based JNK inhibitors with improved pharmacokinetic properties is described. These compounds were designed based on information derived from metabolite identification studies which led to compounds such as 42 with lower clearance, greater brain exposure and longer half life compared to earlier analogs.

Synthesis and SAR exploration of dinapsoline analogues

Dinapsoline is a full D1 dopamine receptor agonist that produces robust rotational activity in the unilateral 6-OHDA rat model. This compound is orally active, and shows a low tendency to cause tolerance in rat models. The active enantiomer was determined to have the S-(+) configuration, and the opposite enantiomer is essentially devoid of biological activity. Taken together, dinapsoline has significant metabolic and pharmacological advantages over previous D1 agonists. In an attempt to define the structure-activity relationships (SARs) and to map out the key elements surrounding the unique structure of dinapsoline, core analogues and substitution analogues of the parent tetracyclic condensed ring structure were prepared. Based on a recently developed synthesis of dinapsoline and its enantiomers, both core and substitution analogues on all four rings (A, B′, C and D ring) of dinapsoline were synthesized. It was found that affinity for both D1and D2 receptors was decreased by most substituents on the A, B′, and C rings, whereas D ring substitutions preserved much of the dopamine receptor binding activity.